Loading…
Legacies of War Recognition and Unexploded Ordnance Removal Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
90pct
104d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Legacies of War Recognition and Unexploded Ordnance Removal Act This bill authorizes the President to provide humanitarian aid to Vietnam, Laos, and Cambodia for (1) the clearance of unexploded ordnance, and (2) assistance for victims of the explosive remnants of war in the region. The President shall annually brief Congress on such assistance activities.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2020 · fourth_quarter · Banking
S. 821, Freedom Financing Act H.R. 2097, Freedom Financing Act, Export Control Act,
Client expense: Not reported · Firm income: $30,000
Ordered to be Reported by Unanimous Consent.
Committee Consideration and Mark-up Session Held.
Referred to the House Committee on Foreign Affairs.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Banking
S. 821, Freedom Financing Act H.R. 2097, Freedom Financing Act, Export Control Act,
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · second_quarter · Health Issues
S. 2960, H. 5965, "Access to Infertility Treatment Act." Legislation to require that health plans offered on the group and individual markets, in addition to the FEHB Program, TRICARE, and the VA provide coverage for in vitro fertility (IVF) treatments and fertility preservation treatments for patients who undergo medically necessary procedures that may cause infertility, such as chemotherapy. H.R. 2097, "The Drug Pricing Transparency Act." Pertaining to manufacturer reporting to CMS of the average sales price (ASP) of products reimbursed by Medicare Part B drugs, specifically including products approved by the FDA as medical devices.
Client expense: $13,500 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
2020 · second_quarter · Banking
S. 821, Freedom Financing Act H.R. 2097, Freedom Financing Act, Export Control Act,
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Health Issues
S. 2960, H. 5965, "Access to Infertility Treatment Act." Legislation to require that health plans offered on the group and individual markets, in addition to the FEHB Program, TRICARE, and the VA provide coverage for in vitro fertility (IVF) treatments and fertility preservation treatments for patients who undergo medically necessary procedures that may cause infertility, such as chemotherapy. H.R. 2097, "The Drug Pricing Transparency Act." Pertaining to manufacturer reporting to CMS of the average sales price (ASP) of products reimbursed by Medicare Part B drugs, specifically including products approved by the FDA as medical devices.
Client expense: $13,500 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
2020 · first_quarter · Banking
S. 821, Freedom Financing Act H.R. 2097, Freedom Financing Act, Export Control Act,
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Health Issues
S. 2960, H. 5965, "Access to Infertility Treatment Act." Legislation to require that health plans offered on the group and individual markets, in addition to the FEHB Program, TRICARE, and the VA provide coverage for in vitro fertility (IVF) treatments and fertility preservation treatments for patients who undergo medically necessary procedures that may cause infertility, such as chemotherapy. H.R. 2097, "The Drug Pricing Transparency Act." Pertaining to manufacturer reporting to CMS of the average sales price (ASP) of products reimbursed by Medicare Part B drugs, specifically including products approved by the FDA as medical devices.
Client expense: $13,500 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
2019 · fourth_quarter · Banking
S. 821, Freedom Financing Act H.R. 2097, Freedom Financing Act, Export Control Act,
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · third_quarter · Banking
S. 821, Freedom Financing Act H.R. 2097, Freedom Financing Act, Export Control Act,
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · second_quarter · Banking
S. 821, Freedom Financing Act H.R. 2097, Freedom Financing Act, Export Control Act,
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · first_quarter · Banking
S. 821, Freedom Financing Act H.R. 2097, Freedom Financing Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| IL |
| Frank Pallone, Jr. | Democratic | NJ |
| Ilhan Omar | Democratic | MN |
| Jackie Speier | Democratic | CA |
| Joaquin Castro | Democratic | TX |
| Michael T. McCaul | Republican | TX |